Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

Switching to long-acting CAB/RPV was not linked to HBV reactivation or incident infection and may be a safe therapeutic option for most patients with HIV.

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

Clin Drug Invest. 2007;27(8):509-531. Antiretroviral drugs (ARVs) can be divided into four different classes according to their modes of action: nucleoside or nucleotide reverse transcriptase ...

Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The ...

BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- ROME Therapeutics, a biotechnology company illuminating the intersection of the dark genome and innate immunity to develop breakthrough medicines for ...

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia. HealthDay News — Exposure to nucleoside reverse transcriptase inhibitors ...

RALEIGH, NC, USA, May 2, 2023/EINPresswire.com/ -- Collaborations Pharmaceuticals, Inc. (CPI) with collaborators at the Research Center of Biotechnology RAS, Moscow ...

Pretreatment drug resistance (PDR) in patients with HIV varies by subtype, affecting antiretroviral therapy implementation and first-line treatment efficacy. In Hangzhou, 8.4% of newly diagnosed HIV ...

The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...